Affiliation:
1. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
Abstract
A 6-year-old boy with ganglioneuroblastoma, received 4 courses of chemotherapy and underwent partial resection of the tumor. The control scintigraphy with 123I-metaiodobenzylguanidine (123I-mIBG) was performed, including the single photon emission computed tomography protocol combined with computed tomography (SPECT/CT), revealing the residual tumor with pathological uptake of 123I-MIBG. In addition to this, there was a focal uptake of 123I-mIBG in the gallbladder. In this clinical case we have demonstrated an atypical uptake of 123I-mIBG in the gallbladder.
Publisher
Non-profit partnership Society of Interventional Oncoradiologists
Reference9 articles.
1. Lonergan GJ, Schwab CM, Suarez ES, et al. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics. 2002 Jul-Aug;22(4):911-34. DOI: 10.1148/ radiographics.22.4.g02jl15911.
2. Sharp SE, Trout AT, Weiss BD, et al. MIBG in Neuroblastoma Diagnostic Imaging and Therapy. Radiographics. 2016 Jan-Feb;36(1):258-78. DOI: 10.1148/rg.2016150099.
3. Agrawal A, Rangarajan V, Shah S, et al. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies. Br J Radiol. 2018 Nov;91(1091):20180103. DOI: 10.1259/bjr.20180103.
4. Nakajo M, Shapiro B, Copp J, et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131] iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med. 1983 Aug;24(8):672-82. PMID: 6135764.
5. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998 Apr;39(4):679-88. PMID: 9544682.